{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:32:39Z","timestamp":1790609559214,"version":"4.1.0"},"publisher-location":"Cham","reference-count":108,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031180699","type":"print"},{"value":"9783031180705","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/82_2020_220","type":"book-chapter","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T08:06:46Z","timestamp":1594109206000},"page":"187-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Regulatory Considerations on the Development of mRNA Vaccines"],"prefix":"10.1007","author":[{"given":"Ramachandra","family":"Naik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Peden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"220_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12026-008-8076-3","volume":"42","author":"SA Abdulhaqq","year":"2008","unstructured":"Abdulhaqq SA, Weiner DB (2008) DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 42:219\u2013232","journal-title":"Immunol Res"},{"key":"220_CR2","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/lary.26737","volume":"127","author":"J Ahn","year":"2017","unstructured":"Ahn J, Peng S, Hung CF, Roden RBS, Wu TC, Best SR (2017) Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7. Laryngoscope 127:2713\u20132720","journal-title":"Laryngoscope"},{"key":"220_CR3","doi-asserted-by":"publisher","first-page":"44875","DOI":"10.1038\/srep44875","volume":"7","author":"SS Al-Amri","year":"2017","unstructured":"Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, Alhabbab RY, Azhar EI, Li X, Hashem AM (2017) Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep 7:44875","journal-title":"Sci Rep"},{"key":"220_CR4","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1093\/nar\/26.15.3550","volume":"26","author":"N Arnaud-Barbe","year":"1998","unstructured":"Arnaud-Barbe N, Cheynet-Sauvion V, Oriol G, Mandrand B, Mallet F (1998) Transcription of RNA templates by T7 RNA polymerase. Nucleic Acids Res 26:3550\u20133554","journal-title":"Nucleic Acids Res"},{"key":"220_CR5","first-page":"163","volume":"17","author":"M Barry","year":"2018","unstructured":"Barry M (2018) Single-cycle adenovirus vectors in the current vaccine landscape. Expert Rev Vaccines 17:163\u2013173","journal-title":"Expert Rev Vaccines"},{"key":"220_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijbiomac.2018.05.198","volume":"118","author":"S Borkotoky","year":"2018","unstructured":"Borkotoky S, Murali A (2018) The highly efficient T7 RNA polymerase: a wonder macromolecule in biological realm. Int J Biol Macromol 118:49\u201356","journal-title":"Int J Biol Macromol"},{"key":"220_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/bs.adgen.2014.10.005","volume":"89","author":"LA Brito","year":"2015","unstructured":"Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW, Dormitzer PR, Ulmer JB, Geall AJ (2015) Self-amplifying mRNA vaccines. Adv Genet 89:179\u2013233","journal-title":"Adv Genet"},{"key":"220_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0065-2776(02)80013-X","volume":"80","author":"PW Bryant","year":"2002","unstructured":"Bryant PW, Lennon-Dumenil AM, Fiebiger E, Lagaudriere-Gesbert C, Ploegh HL (2002) Proteolysis and antigen presentation by MHC class II molecules. Adv Immunol 80:71\u2013114","journal-title":"Adv Immunol"},{"key":"220_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/B978-0-12-417028-5.00008-9","volume":"120","author":"S Cerboni","year":"2013","unstructured":"Cerboni S, Gentili M, Manel N (2013) Diversity of pathogen sensors in dendritic cells. Adv Immunol 120:211\u2013237","journal-title":"Adv Immunol"},{"key":"220_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/iub.1625","volume":"69","author":"N Chen","year":"2017","unstructured":"Chen N, Xia P, Li S, Zhang T, Wang TT, Zhu J (2017) RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69:297\u2013304","journal-title":"IUBMB Life"},{"key":"220_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1089\/hum.2017.197","volume":"29","author":"MA Cheng","year":"2018","unstructured":"Cheng MA, Farmer E, Huang C, Lin J, Hung CF, Wu TC (2018) Therapeutic DNA vaccines for human Papillomavirus and associated diseases. Hum Gene Ther 29:971\u2013996","journal-title":"Hum Gene Ther"},{"key":"220_CR12","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.vaccine.2017.02.063","volume":"35","author":"H Chi","year":"2017","unstructured":"Chi H, Zheng X, Wang X, Wang C, Wang H, Gai W, Perlman S, Yang S, Zhao J, Xia X (2017) DNA vaccine encoding middle east respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine 35:2069\u20132075","journal-title":"Vaccine"},{"key":"220_CR13","first-page":"1397","volume":"55","author":"RM Conry","year":"1995","unstructured":"Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, Benjamin R, Lu D, Curiel DT (1995) Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55:1397\u20131400","journal-title":"Cancer Res"},{"key":"220_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.coi.2013.09.011","volume":"25","author":"SP Crampton","year":"2013","unstructured":"Crampton SP, Bolland S (2013) Spontaneous activation of RNA-sensing pathways in autoimmune disease. Curr Opin Immunol 25:712\u2013719","journal-title":"Curr Opin Immunol"},{"key":"220_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","volume":"34","author":"M Fotin-Mleczek","year":"2011","unstructured":"Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, Kallen KJ (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34:1\u201315","journal-title":"J Immunother"},{"key":"220_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jgm.2605","volume":"14","author":"M Fotin-Mleczek","year":"2012","unstructured":"Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, Kallen KJ (2012) Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med 14:428\u2013439","journal-title":"J Gene Med"},{"key":"220_CR17","doi-asserted-by":"crossref","unstructured":"Freund I, Eigenbrod T, Helm M, Dalpke AH. 2019. RNA Modifications Modulate Activation of Innate Toll-Like Receptors. Genes (Basel) 10","DOI":"10.3390\/genes10020092"},{"key":"220_CR18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.yexcr.2012.03.032","volume":"318","author":"R Fukui","year":"2012","unstructured":"Fukui R, Miyake K (2012) Controlling systems of nucleic acid sensing-TLRs restrict homeostatic inflammation. Exp Cell Res 318:1461\u20131466","journal-title":"Exp Cell Res"},{"key":"220_CR19","doi-asserted-by":"publisher","first-page":"8164","DOI":"10.4049\/jimmunol.177.11.8164","volume":"177","author":"KK Gorden","year":"2006","unstructured":"Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS (2006a) Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol 177:8164\u20138170","journal-title":"J Immunol"},{"key":"220_CR20","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.4049\/jimmunol.177.10.6584","volume":"177","author":"KK Gorden","year":"2006","unstructured":"Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS (2006b) Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 177:6584\u20136587","journal-title":"J Immunol"},{"key":"220_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","volume":"18","author":"S Gurunathan","year":"2000","unstructured":"Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 18:927\u2013974","journal-title":"Annu Rev Immunol"},{"key":"220_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, Himansu S, Deterling J, Geilich BM, Ketova T, Mihai C, Lynn A, McFadyen I, Moore MJ, Senn JJ, Stanton MG, Almarsson O, Ciaramella G, Brito LA (2019) Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids 15:1\u201311","journal-title":"Mol Ther Nucleic Acids"},{"key":"220_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","volume":"3","author":"H Hemmi","year":"2002","unstructured":"Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196\u2013200","journal-title":"Nat Immunol"},{"key":"220_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-1-4939-6481-9_13","volume":"1499","author":"T Hinz","year":"2017","unstructured":"Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Tureci O, Kalinke U (2017) The European regulatory environment of RNA-based vaccines. Methods Mol Biol 1499:203\u2013222","journal-title":"Methods Mol Biol"},{"key":"220_CR26","doi-asserted-by":"crossref","unstructured":"Hobernik D, Bros M (2018) DNA vaccines-how far from clinical use? Int J Mol Sci 19","DOI":"10.3390\/ijms19113605"},{"key":"220_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","volume":"30","author":"I Hoerr","year":"2000","unstructured":"Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1\u20137","journal-title":"Eur J Immunol"},{"key":"220_CR28","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.vaccine.2006.03.058","volume":"24","author":"J Huang","year":"2006","unstructured":"Huang J, Ma R, Wu CY (2006) Immunization with SARS-CoV S DNA vaccine generates memory CD4+\u2009and CD8+\u2009T cell immune responses. Vaccine 24:4905\u20134913","journal-title":"Vaccine"},{"key":"220_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semcdb.2014.05.018","volume":"34","author":"AL Jalkanen","year":"2014","unstructured":"Jalkanen AL, Coleman SJ, Wilusz J (2014) Determinants and implications of mRNA poly(A) tail size\u2013does this protein make my tail look big? Semin Cell Dev Biol 34:24\u201332","journal-title":"Semin Cell Dev Biol"},{"key":"220_CR30","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1261\/rna.5430403","volume":"9","author":"J Jemielity","year":"2003","unstructured":"Jemielity J, Fowler T, Zuberek J, Stepinski J, Lewdorowicz M, Niedzwiecka A, Stolarski R, Darzynkiewicz E, Rhoads RE (2003) Novel \u201canti-reverse\u201d cap analogs with superior translational properties. RNA 9:1108\u20131122","journal-title":"RNA"},{"key":"220_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.gde.2012.12.004","volume":"23","author":"J Jia","year":"2013","unstructured":"Jia J, Yao P, Arif A, Fox PL (2013) Regulation and dysregulation of 3\u2019UTR-mediated translational control. Curr Opin Genet Dev 23:29\u201334","journal-title":"Curr Opin Genet Dev"},{"key":"220_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ni0602-499","volume":"3","author":"M Jurk","year":"2002","unstructured":"Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3:499","journal-title":"Nat Immunol"},{"key":"220_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","volume":"9","author":"JC Kaczmarek","year":"2017","unstructured":"Kaczmarek JC, Kowalski PS, Anderson DG (2017) Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med 9:60","journal-title":"Genome Med"},{"key":"220_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/2051013613508729","volume":"2","author":"KJ Kallen","year":"2014","unstructured":"Kallen KJ, Thess A (2014) A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2:10\u201331","journal-title":"Ther Adv Vaccines"},{"key":"220_CR35","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.4161\/hv.25181","volume":"9","author":"KJ Kallen","year":"2013","unstructured":"Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M (2013) A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines. Hum Vaccin Immunother 9:2263\u20132276","journal-title":"Hum Vaccin Immunother"},{"key":"220_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165\u2013175","journal-title":"Immunity"},{"key":"220_CR37","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Kariko","year":"2008","unstructured":"Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16:1833\u20131840","journal-title":"Mol Ther"},{"key":"220_CR38","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","volume":"39","author":"K Kariko","year":"2011","unstructured":"Kariko K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39:e142","journal-title":"Nucleic Acids Res"},{"key":"220_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mib.2014.05.005","volume":"20","author":"E Kindler","year":"2014","unstructured":"Kindler E, Thiel V (2014) To sense or not to sense viral RNA\u2014essentials of coronavirus innate immune evasion. Curr Opin Microbiol 20:69\u201375","journal-title":"Curr Opin Microbiol"},{"key":"220_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00870272","volume":"19","author":"DM Klinman","year":"1997","unstructured":"Klinman DM, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G, Conover J (1997) DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol 19:245\u2013256","journal-title":"Springer Semin Immunopathol"},{"key":"220_CR41","first-page":"45","volume":"104","author":"DM Klinman","year":"2000","unstructured":"Klinman DM, Takeshita F, Kamstrup S, Takeshita S, Ishii K, Ichino M, Yamada H (2000) DNA vaccines: capacity to induce auto-immunity and tolerance. Dev Biol (Basel) 104:45\u201351","journal-title":"Dev Biol (Basel)"},{"key":"220_CR42","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski PS, Rudra A, Miao L, Anderson DG (2019) Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther 27:710\u2013728","journal-title":"Mol Ther"},{"key":"220_CR43","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.1093\/nar\/12.18.7057","volume":"12","author":"PA Krieg","year":"1984","unstructured":"Krieg PA, Melton DA (1984) Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res 12:7057\u20137070","journal-title":"Nucleic Acids Res"},{"key":"220_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0076-6879(87)55027-3","volume":"155","author":"PA Krieg","year":"1987","unstructured":"Krieg PA, Melton DA (1987) In vitro RNA synthesis with SP6 RNA polymerase. Methods Enzymol 155:397\u2013415","journal-title":"Methods Enzymol"},{"key":"220_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, van der Meel R (2018) Lipid Nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther 28:146\u2013157","journal-title":"Nucleic Acid Ther"},{"key":"220_CR46","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"MA Kutzler","year":"2008","unstructured":"Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776\u2013788","journal-title":"Nat Rev Genet"},{"key":"220_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/978-1-62703-110-3_27","volume":"940","author":"B Langer","year":"2013","unstructured":"Langer B, Renner M, Scherer J, Schule S, Cichutek K (2013) Safety assessment of biolistic DNA vaccination. Methods Mol Biol 940:371\u2013388","journal-title":"Methods Mol Biol"},{"key":"220_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000053993","volume":"43","author":"BJ Ledwith","year":"2000","unstructured":"Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG, Harper LB, Beare CM, Bagdon WJ, Nichols WW (2000) Plasmid DNA vaccines: Investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 43:258\u2013272","journal-title":"Intervirology"},{"key":"220_CR49","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1073\/pnas.0631696100","volume":"100","author":"J Lee","year":"2003","unstructured":"Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, Cottam HB (2003) Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of toll-like receptor 7. Proc Natl Acad Sci U S A 100:6646\u20136651","journal-title":"Proc Natl Acad Sci U S A"},{"key":"220_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.actbio.2018.08.033","volume":"80","author":"J Lee","year":"2018","unstructured":"Lee J, Arun Kumar S, Jhan YY, Bishop CJ (2018) Engineering DNA vaccines against infectious diseases. Acta Biomater 80:31\u201347","journal-title":"Acta Biomater"},{"key":"220_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","volume":"162","author":"L Li","year":"2012","unstructured":"Li L, Saade F, Petrovsky N (2012) The future of human DNA vaccines. J Biotechnol 162:171\u2013182","journal-title":"J Biotechnol"},{"key":"220_CR52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"H Lv","year":"2006","unstructured":"Lv H, Zhang S, Wang B, Cui S, Yan J (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114:100\u2013109","journal-title":"J Control Release"},{"key":"220_CR53","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier MA, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, Tam YK, Ansell SM, Kumar V, Qin J, Zhang X, Wang Q, Panesar S, Hutabarat R, Carioto M, Hettinger J, Kandasamy P, Butler D, Rajeev KG, Pang B, Charisse K, Fitzgerald K, Mui BL, Du X, Cullis P, Madden TD, Hope MJ, Manoharan M, Akinc A (2013) Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther 21:1570\u20131578","journal-title":"Mol Ther"},{"key":"220_CR54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000053994","volume":"43","author":"S Manam","year":"2000","unstructured":"Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Griffiths TG 2nd, Niu Z, Denisova L, Follmer TT, Pacchione SJ, Wang Z, Beare CM, Bagdon WJ, Nichols WW (2000) Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43:273\u2013281","journal-title":"Intervirology"},{"key":"220_CR55","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1615\/CritRevImmunol.v37.i2-6.140","volume":"37","author":"E Manickan","year":"2017","unstructured":"Manickan E, Karem KL, Rouse BT (2017) DNA vaccines\u2014a modern gimmick or a boon to vaccinology? Crit Rev Immunol 37:483\u2013498","journal-title":"Crit Rev Immunol"},{"key":"220_CR56","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/eji.1830230749","volume":"23","author":"F Martinon","year":"1993","unstructured":"Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet JG, Levy JP, Meulien P (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719\u20131722","journal-title":"Eur J Immunol"},{"key":"220_CR57","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi G, Zhang C, Li J, Ulmer JB, Yu D (2019) mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther 27:757\u2013772","journal-title":"Mol Ther"},{"key":"220_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/rmv.680","volume":"21","author":"M Matsumoto","year":"2011","unstructured":"Matsumoto M, Oshiumi H, Seya T (2011) Antiviral responses induced by the TLR3 pathway. Rev Med Virol 21:67\u201377","journal-title":"Rev Med Virol"},{"key":"220_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40259-018-0261-x","volume":"32","author":"VP Mauro","year":"2018","unstructured":"Mauro VP (2018) Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations. BioDrugs 32:69\u201381","journal-title":"BioDrugs"},{"key":"220_CR60","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","volume":"20","author":"VP Mauro","year":"2014","unstructured":"Mauro VP, Chappell SA (2014) A critical analysis of codon optimization in human therapeutics. Trends Mol Med 20:604\u2013613","journal-title":"Trends Mol Med"},{"key":"220_CR61","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-4939-8730-6_18","volume":"1850","author":"VP Mauro","year":"2018","unstructured":"Mauro VP, Chappell SA (2018) Considerations in the use of codon optimization for recombinant protein expression. Methods Mol Biol 1850:275\u2013288","journal-title":"Methods Mol Biol"},{"key":"220_CR62","unstructured":"Medjitna TD, Stadler C, Bruckner L, Griot C, Ottiger HP (2006) DNA vaccines: safety aspect assessment and regulation. Dev Biol (Basel) 126:261\u2013270; discussion 327"},{"key":"220_CR63","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731\u20132738","journal-title":"J Immunol"},{"key":"220_CR64","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/14760584.2015.986104","volume":"14","author":"P Midoux","year":"2015","unstructured":"Midoux P, Pichon C (2015) Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines 14:221\u2013234","journal-title":"Expert Rev Vaccines"},{"key":"220_CR65","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN (2019) Safety and immunogenicity of an anti-middle east respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 19:1013\u20131022","journal-title":"Lancet Infect Dis"},{"key":"220_CR66","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-17-2335","volume":"24","author":"MP Morrow","year":"2018","unstructured":"Morrow MP, Kraynyak KA, Sylvester AJ, Dallas M, Knoblock D, Boyer JD, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY, Kim JJ, Plotkin S, Weiner DB, Trimble CL, Bagarazzi ML (2018) Clinical and immunologic biomarkers for histologic regression of high-grade cervical dysplasia and clearance of HPV16 and HPV18 after immunotherapy. Clin Cancer Res 24:276\u2013294","journal-title":"Clin Cancer Res"},{"key":"220_CR67","doi-asserted-by":"crossref","unstructured":"Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, Scott DP, Feldmann F, LaCasse R, Meade-White K, Okumura A, Ugen KE, Sardesai NY, Kim JJ, Kobinger G, Feldmann H, Weiner DB (2015) A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 7:301ra132","DOI":"10.1126\/scitranslmed.aac7462"},{"key":"220_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/infdis\/jiw111","volume":"214","author":"K Muthumani","year":"2016","unstructured":"Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari P, Sardesai NY, Kim JJ, Ugen KE, Weiner DB (2016) Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya Virus. J Infect Dis 214:369\u20133678","journal-title":"J Infect Dis"},{"key":"220_CR69","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21775\/cimb.022.079","volume":"22","author":"AI Myhr","year":"2017","unstructured":"Myhr AI (2017) DNA vaccines: regulatory considerations and safety aspects. Curr Issues Mol Biol 22:79\u201388","journal-title":"Curr Issues Mol Biol"},{"key":"220_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-59745-248-9_2","volume":"703","author":"H Nielsen","year":"2011","unstructured":"Nielsen H (2011) Working with RNA. Methods Mol Biol 703:15\u201328","journal-title":"Methods Mol Biol"},{"key":"220_CR71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","volume":"1499","author":"N Pardi","year":"2017","unstructured":"Pardi N, Weissman D (2017) Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol 1499:109\u2013121","journal-title":"Methods Mol Biol"},{"key":"220_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","volume":"969","author":"N Pardi","year":"2013","unstructured":"Pardi N, Muramatsu H, Weissman D, Kariko K (2013) In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol 969:29\u201342","journal-title":"Methods Mol Biol"},{"key":"220_CR73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov 17:261\u2013279","journal-title":"Nat Rev Drug Discov"},{"key":"220_CR74","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1517\/14712598.4.8.1285","volume":"4","author":"S Pascolo","year":"2004","unstructured":"Pascolo S (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4:1285\u20131294","journal-title":"Expert Opin Biol Ther"},{"key":"220_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-72167-3_11:221-235","author":"S Pascolo","year":"2008","unstructured":"Pascolo S (2008) Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/978-3-540-72167-3_11:221-235","journal-title":"Handb Exp Pharmacol"},{"key":"220_CR76","unstructured":"Plotkin SA, Orenstein WA, Offit PA, Edwards KM (2017) Plotkin\u2019s vaccines, 7th ed. Elsevier Saunders"},{"key":"220_CR77","doi-asserted-by":"publisher","first-page":"129","DOI":"10.21775\/cimb.022.129","volume":"22","author":"KR Porter","year":"2017","unstructured":"Porter KR, Raviprakash K (2017) DNA vaccine delivery and improved immunogenicity. Curr Issues Mol Biol 22:129\u2013138","journal-title":"Curr Issues Mol Biol"},{"key":"220_CR78","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01184-15:10407-10415","author":"TD Reynolds","year":"2015","unstructured":"Reynolds TD, Buonocore L, Rose NF, Rose JK, Robek MD (2015) Virus-like vesicle-based therapeutic vaccine vectors for chronic Hepatitis B virus infection. J Virol. https:\/\/doi.org\/10.1128\/jvi.01184-15:10407-10415","journal-title":"J Virol"},{"key":"220_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(02)80012-8","volume":"80","author":"KL Rock","year":"2002","unstructured":"Rock KL, York IA, Saric T, Goldberg AL (2002) Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 80:1\u201370","journal-title":"Adv Immunol"},{"key":"220_CR80","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","volume":"37","author":"KL Rock","year":"2016","unstructured":"Rock KL, Reits E, Neefjes J (2016) Present yourself! By MHC class I and MHC class II molecules. Trends Immunol 37:724\u2013737","journal-title":"Trends Immunol"},{"key":"220_CR81","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1073\/pnas.0800280105","volume":"105","author":"NF Rose","year":"2008","unstructured":"Rose NF, Publicover J, Chattopadhyay A, Rose JK (2008) Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors. Proc Natl Acad Sci U S A 105:5839\u20135843","journal-title":"Proc Natl Acad Sci U S A"},{"key":"220_CR82","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erv.11.188","volume":"11","author":"F Saade","year":"2012","unstructured":"Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11:189\u2013209","journal-title":"Expert Rev Vaccines"},{"key":"220_CR83","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","volume":"9","author":"T Schlake","year":"2012","unstructured":"Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (2012) Developing mRNA-vaccine technologies. RNA Biol 9:1319\u20131330","journal-title":"RNA Biol"},{"key":"220_CR84","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00018-018-2935-4","volume":"76","author":"T Schlake","year":"2019","unstructured":"Schlake T, Thess A, Thran M, Jordan I (2019) mRNA as novel technology for passive immunotherapy. Cell Mol Life Sci 76:301\u2013328","journal-title":"Cell Mol Life Sci"},{"key":"220_CR85","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0300985817738095","volume":"55","author":"M Sedic","year":"2018","unstructured":"Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, Bolen J, Hoge S, Bulychev A, Jacquinet E, Bartlett V, Smith PF (2018) Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Vet Pathol 55:341\u2013354","journal-title":"Vet Pathol"},{"key":"220_CR86","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1134\/S0006297916070075","volume":"81","author":"OV Sergeeva","year":"2016","unstructured":"Sergeeva OV, Koteliansky VE, Zatsepin TS (2016) mRNA-based therapeutics\u2014advances and perspectives. Biochemistry (Mosc) 81:709\u2013722","journal-title":"Biochemistry (Mosc)"},{"key":"220_CR87","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/toxsci\/kfj170","volume":"91","author":"RL Sheets","year":"2006","unstructured":"Sheets RL, Stein J, Manetz TS, Andrews C, Bailer R, Rathmann J, Gomez PL (2006a) Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol Sci 91:620\u2013630","journal-title":"Toxicol Sci"},{"key":"220_CR88","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/toxsci\/kfj169","volume":"91","author":"RL Sheets","year":"2006","unstructured":"Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL (2006b) Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 91:610\u2013619","journal-title":"Toxicol Sci"},{"key":"220_CR89","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.molmed.2006.02.004","volume":"12","author":"M Sioud","year":"2006","unstructured":"Sioud M (2006) Innate sensing of self and non-self RNAs by toll-like receptors. Trends Mol Med 12:167\u2013176","journal-title":"Trends Mol Med"},{"key":"220_CR90","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1093\/nar\/gkx135","volume":"45","author":"YV Svitkin","year":"2017","unstructured":"Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N (2017) N1-methyl-pseudouridine in mRNA enhances translation through eIF2alpha-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res 45:6023\u20136036","journal-title":"Nucleic Acids Res"},{"key":"220_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4939-6481-9_2","volume":"1499","author":"BA Tews","year":"2017","unstructured":"Tews BA, Meyers G (2017) Self-replicating RNA. Methods Mol Biol 1499:15\u201335","journal-title":"Methods Mol Biol"},{"key":"220_CR92","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.15252\/emmm.201707678","volume":"9","author":"M Thran","year":"2017","unstructured":"Thran M, Mukherjee J, Ponisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, Fotin-Mleczek M, Shoemaker CB, Schlake T (2017) mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med 9:1434\u20131447","journal-title":"EMBO Mol Med"},{"key":"220_CR93","doi-asserted-by":"crossref","unstructured":"Tregoning JS, Kinnear E (2014) Using plasmids as DNA vaccines for infectious diseases. Microbiol Spectr 2","DOI":"10.1128\/microbiolspec.PLAS-0028-2014"},{"key":"220_CR94","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/CVI.00031-12","volume":"19","author":"Y Uematsu","year":"2012","unstructured":"Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, Galli G, Saletti G, Otten GR, Rappuoli R, Barnett SW, Polo JM (2012) Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol 19:991\u2013998","journal-title":"Clin Vaccine Immunol"},{"key":"220_CR95","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1016\/j.vaccine.2012.04.060","volume":"30","author":"JB Ulmer","year":"2012","unstructured":"Ulmer JB, Mason PW, Geall A, Mandl CW (2012) RNA-based vaccines. Vaccine 30:4414\u20134418","journal-title":"Vaccine"},{"key":"220_CR96","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","volume":"32","author":"B Weide","year":"2009","unstructured":"Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C (2009) Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients. J Immunother 32:498\u2013507","journal-title":"J Immunother"},{"key":"220_CR97","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1586\/14760584.2015.973859","volume":"14","author":"D Weissman","year":"2015","unstructured":"Weissman D (2015) mRNA transcript therapy. Expert Rev Vaccines 14:265\u2013281","journal-title":"Expert Rev Vaccines"},{"key":"220_CR98","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/mt.2015.138","volume":"23","author":"D Weissman","year":"2015","unstructured":"Weissman D, Kariko K (2015) mRNA: fulfilling the promise of gene therapy. Mol Ther 23:1416\u20131417","journal-title":"Mol Ther"},{"key":"220_CR99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","volume":"969","author":"D Weissman","year":"2013","unstructured":"Weissman D, Pardi N, Muramatsu H, Kariko K (2013) HPLC purification of in vitro transcribed long RNA. Methods Mol Biol 969:43\u201354","journal-title":"Methods Mol Biol"},{"key":"220_CR100","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129\u2013138","journal-title":"Nat Rev Drug Discov"},{"key":"220_CR101","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0968-0004(03)00051-3","volume":"28","author":"GS Wilkie","year":"2003","unstructured":"Wilkie GS, Dickson KS, Gray NK (2003) Regulation of mRNA translation by 5\u2019- and 3\u2019-UTR-binding factors. Trends Biochem Sci 28:182\u2013188","journal-title":"Trends Biochem Sci"},{"key":"220_CR102","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/156652321403140819122538","volume":"14","author":"JA Williams","year":"2014","unstructured":"Williams JA (2014) Improving DNA vaccine performance through vector design. Curr Gene Ther 14:170\u2013189","journal-title":"Curr Gene Ther"},{"key":"220_CR103","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465\u20131468","journal-title":"Science"},{"key":"220_CR104","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-032713-120156","volume":"32","author":"J Wu","year":"2014","unstructured":"Wu J, Chen ZJ (2014) Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 32:461\u2013488","journal-title":"Annu Rev Immunol"},{"key":"220_CR105","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1089\/dna.2007.0616","volume":"26","author":"AN Zakhartchouk","year":"2007","unstructured":"Zakhartchouk AN, Viswanathan S, Moshynskyy I, Petric M, Babiuk LA (2007) Optimization of a DNA vaccine against SARS. DNA Cell Biol 26:721\u2013726","journal-title":"DNA Cell Biol"},{"key":"220_CR106","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Maruggi G, Shan H, Li J (2019) Advances in mRNA vaccines for infectious diseases. Front Immunol 10:594","journal-title":"Front Immunol"},{"key":"220_CR107","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1089\/10430349950016762","volume":"10","author":"WZ Zhou","year":"1999","unstructured":"Zhou WZ, Hoon DS, Huang SK, Fujii S, Hashimoto K, Morishita R, Kaneda Y (1999) RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther 10:2719\u20132724","journal-title":"Hum Gene Ther"},{"key":"220_CR108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/ph6010085","volume":"6","author":"J Zhou","year":"2013","unstructured":"Zhou J, Shum KT, Burnett JC, Rossi JJ (2013) Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals (Basel) 6:85\u2013107","journal-title":"Pharmaceuticals (Basel)"},{"key":"220_CR109","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1093\/nar\/gkt1193","volume":"42","author":"B Zhu","year":"2014","unstructured":"Zhu B, Tabor S, Richardson CC (2014) Syn5 RNA polymerase synthesizes precise run-off RNA products. Nucleic Acids Res 42:e33","journal-title":"Nucleic Acids Res"}],"container-title":["Current Topics in Microbiology and Immunology","mRNA Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2020_220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T14:12:48Z","timestamp":1678371168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2020_220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783031180699","9783031180705"],"references-count":108,"URL":"https:\/\/doi.org\/10.1007\/82_2020_220","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"8 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}